EGFR inhibitors Inhibikase Therapeutics

N/A

Report date: 2026/05/14 20:00:28
NME

Base Information

Drug NameEGFR inhibitors Inhibikase Therapeutics
Drug Alias Nameepidermal growth factor receptor inhibitors (Inhibikase Therapeutics)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesInhibikase Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInhibikase Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsHepatitis C

Other Information

ATC CodeN/A
Related LinksN/A